“…Influenza causes substantive economic and disease burden in Peru that results in high rates of hospitalizations and deaths [1] , [2] , [3] , [4] . To mitigate this burden, each year Peru’s government purchases one trivalent inactivated influenza vaccine product though the Pan American Health Organization and provides doses free of charge for target groups identified by the World Health Organization (WHO) Strategic Advisory Group of Experts (SAGE) [5] ; these target groups include young children, pregnant women, older adults, individuals with comorbidities, and healthcare personnel (HCP). Despite a national program for HCP influenza vaccination, knowledge, attitudes, and practices (KAP) of these SAGE target groups suggest that HCP insufficiently receive and recommend influenza vaccination in Peru [6] , [7] , [8] , possibly because of ambivalence about individuals’ risk of influenza illness or the value of influenza vaccination [9] .…”